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Objectives: To investigate the subjective treat-
ment goals of insulin-treated diabetic patients 
Methods: 297 type 1 and 205 type 2 diabetic pa-
tients, representative of the North-western Swiss
population, filled out a self report questionnaire
focusing on their own treatment goals using stan-
dardized measures wherever available. Factor
analysis of the 16 items reflecting their treatment
goals revealed four subscales (Crohnbach’s alpha):
High actual quality of life (0.73), weight reduc-
tion/maintenance and daily hassles (0.68), good
medical care and knowledge (0.64) and good long
term glucose control (0.71). 
Results: Good long term glucose control was
the single most important main treatment goal 
for most patients (type 1: 60.2%, type 2: 49.7%, 
p = 0.025). However, both type 1 and type 2 dia-
betic patients believed that this goal – especially
the value of HbA1c – was overestimated (both 
p <0.0001), while high actual quality of life was un-
derestimated (p = 0.003 and p = 0.05, respectively)
by their physicians compared to their own assess-
ment. Good long term glucose control (OR 1.63,
p = 0.003) and high actual quality of life (OR 2.17,
p <0.0001) were more important and weight re-
duction/maintenance and coping with daily hassles
(OR 0.75, p = 0.07) were slightly less important
treatment goals for type 1 than for type 2 diabetic
patients. These differences in goals were best as-
sociated with the mode of insulin therapy, self-
monitoring, and with the extent of diabetes educa-
tion. 
Conclusions: Patients believe that physicians
overestimate the importance of long term glucose
control and underestimate the importance of ac-
tual quality of life. Diabetes education and self
management have the largest impact on patients’
own treatment goals.
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Quality of life is affected in patients with dia-
betes [1, 2] and insulin treatment further influ-
ences the impact of the disease on quality of life
[2]. On the other side, patient empowerment and
self-management can increase quality of life and
patient satisfaction [3, 4] as well as metabolic con-
trol [5–7]. Patients’ autonomy is further potenti-
ated when treatment goals are tailored to their own
treatment goals [8]. Despite this, there are hardly
any published data on patients’ own treatment
goals, and it is generally assumed to be in the pa-
tient’s interest that certain goals are achieved [9].
One study demonstrated that type 1 diabetic pa-
tients found good glucose control, flexibility,
avoidance of late complications as well as absence
of severe hypoglycaemia to be very important goals
[10] and almost all queried items were given a high
priority. Furthermore, the questionnaire was not
anonymous, and thus more vulnerable to biases
such as social desirability. 
In an exploratory pilot study, we investigated
the main treatment goals of insulin-treated dia-
betic patients [11]. The results indicated that long
term blood glucose control and actual quality of
life were more important for type 1 than for type
2 diabetic patients. These patients also believed
that their physicians overestimated the importance
of long term glucose control [11]. In the current
study, we asked the following questions: Is long
term glucose control indeed the single most im-
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portant main treatment goal of insulin-treated di-
abetic patients? Do patients believe that their
physicians have different treatment goals com-
pared to themselves? Can we confirm that there
are differences in treatment goals between insulin-
treated type 1 and type 2 diabetic patients and what
factors determine these differences? 
Subject and methods
Patients
This study examined a sample of 509 German speak-
ing insulin-treated diabetic patients (297 type 1 and 205
type 2 diabetic patients) that are representative of the
North-western Swiss population. They were recruited
from the diabetes outpatient clinic of the University of
Basel Hospital (n = 203), the other 5 regional hospitals in
this area (n = 135), 13 of 14 specialist practices (n = 107)
and 15 randomly selected general practitioner practices 
(n = 64). Each general practitioner and each specialist dis-
tributed the questionnaire consecutively to 6–10 patients
respectively within a time period of 2 months. The ques-
tionnaires were sent to all insulin-treated diabetic patients
in our outpatient clinic. Anonymity was ensured. Overall,
636 questionnaires were distributed and 80% were an-
swered and returned. The characteristics of the patients
are presented in Table 1. The human research ethics com-
mittee of the University of Basel approved the study.
Development of the questionnaire 
Our 83-item self report questionnaire was developed
through a three-step procedure. First, the authors re-
viewed existing questionnaires and articles and a self re-
port questionnaire was distributed to 124 patients with in-
sulin-treated diabetes in a qualitative pilot study investi-
gating patients’ treatment goals for diabetes-related behaviour,
diabetes-related worries and satisfaction with medical care [11],
with questions from the Diabetes Quality of Life (DQOL)
Questionnaire [12]. Based on this information, we con-
structed a set of items for these three scales and obtained
feedback from diabetes specialists, diabetes educators and
psychologists. Wherever possible we used scales from
other validated questionnaires. To be able to better com-
pare both types of diabetes, the same questionnaire was
used for patients with type 1 and with type 2 diabetes. This
German-speaking questionnaire is available on the web-
site of the Swiss Medical Weekly: http://www.smw.ch/
dfe/set_archiv.asp 3 Archive 3 issue 35-36, 2006). 
Measures
In addition to sociodemographic questions, the ques-
tionnaire asked about the type of diabetes, weight and
height, the mode of insulin therapy (conventional, basis-
bolus or functional insulin therapy), self-monitoring (fre-
quency of blood glucose measurements and insulin in-
jections) and the extent of diabetes education, glucose
control (diabetes duration, HbA1c, number of mild and
severe hypoglycaemic events) and diabetic complications
(Table 1). Severe hypoglycaemic events were defined as in
the Diabetes Controls and Complications Trial [13]. 
Quality of life 
Quality of life was assessed using the validated Ger-
man translation of the two overview items (quality of life
per se and impact of diabetes on quality of life) of the Audit
of Diabetes-Dependent Quality of Life (ADDQoL) ques-
tionnaire [2], where we slightly modified the explanatory
introducing sentence. The overview item of quality of life
has been shown to be useful in the DAFNE trial [14]. 
Internality
Internality was assessed using the scale internality
from the IPC diabetes questionnaire consisting of 8 items
[15]. 
Treatment goals for diabetes-related behaviour
Questions were generated to evaluate the importance
of 16 different treatment goals incorporating questions
from previous questionnaires [10, 11, 16]. However, we
did not find any published validation of these cited ques-
tions. 
Main treatment goals
Patients were asked to mention their single most im-
portant main treatment goal among the 16 goals (below)
as well as the main treatment goal they thought that their
physicians had. These two responses were used to address
a potential discrepancy between patients’ main goals and
the perceived physicians’ main goals. 
Treatment goals
Patients rated all 16 goals on a scale ranging from 1
(totally unimportant) to 6 (very important). No items were
eliminated. The following four subscales were derived
from the principal component analysis with subsequent
varimax rotation:
1. High actual quality of life (Eigenvalue = 5.7, Crohn-
bach’s α 0.73): Importance of good quality of life, flexible
diet, flexible life, physical efficiency, self efficiency, disci-
pline
2. Weight reduction/maintenance and avoidance of daily
hassles (Eigenvalue = 1.7, Crohnbach’s α 0.68): Importance
of weight reduction/maintenance or of avoidance of either
blood glucose monitoring or of insulin injections
3. Good medical care and knowledge (Eigenvalue = 1.6,
Crohnbach’s α 0.64): Importance of medical therapy,
knowledge, avoidance of hypoglycaemia
4. Good long term glucose control (Eigenvalue = 1.1,
Crohnbach’s α 0.71): Importance of good HbA1c, avoid-
ance of complications, avoidance of blood glucose fluctu-
ations, disease acceptance
Diabetes-related worries
Questions were generated to evaluate the impact of
10 different worries, 8 of them having been previously
used in the DQOL and/or the diabetes-specific quality-
of-life scale (DSQOLS) questionnaire (10, 12). In analogy
with the DQOL, we used a five-point scale for each ques-
tion ranging from 1 (“never worries, restricts or exhausts
me”) to 5 (“always worries, restricts or exhausts me”). No
items were eliminated. 
The following two subscales were derived from the
principal component analysis with subsequent varimax
rotation:
1. Diabetes-related physical complaints and worries about
dietary restriction (Eigenvalue 4.2, Crohnbach’s α 0.74):
Exhaustion or lack of energy due to either diabetes or high
blood glucose, restriction by diet
2. General diabetes-related worries (Eigenvalue 1.3,
Crohnbach’s α 0.73): Restriction in flexibility or in phys-
ical activity, worries about complications, hypoglycaemia,
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hyperglycaemia, weight reduction, impact of diabetes on
social life
Satisfaction with medical care
Six questions were generated to assess the patient-
physician relationship, rated on a scale ranging from 1
(“never”) to 4 (“always”). The following single subscale
was derived from the principal component analysis:
Satisfaction with medical care (Crohnbach’s α 0.76):
Telling physician everything about diabetes, physician ac-
cepts the way patients handle their diabetes, satisfaction
with medical care, patients’ questions adequately an-
swered by their physician, sufficient time spent with their
physician during consultation and being able to contact
their physician as needed. 
One question was added rating the importance of a
diabetes team (physician, diabetes educators, psycholo-
gists) in their diabetes treatment. 
Statistical analysis
We estimated our sample size based on the differ-
ences in their most important treatment goal (glucose con-
trol, 67% vs 40%) between the type 1 and type 2 diabetic
patients and between patients and their physicians’ esti-
mate (63 vs 86%) found in our pilot study [11]. Assuming
a type I error rate of 5% and a type II error rate of 10%
Type 1 diabetic Type 2 diabetic P
patients (n = 297) patients (n = 205)
Age (yrs) 45.4 ± 17.9 63.0 ± 9.9 <0.001
Sex (m/f) (%) 46/54 63/37 <0.0001
Married (%) 53 71 <0.0001
Level of education (%) 0.03
Up to 9th grade 26 30
10–12th grade 40 47
Over 12th grade 34 23
Employment status (% employed) 45 23 <0.0001
Region of origin (Central Europe, 87/9/4 92/5/3 0.25
Mediterranean [Italy, Turkey], other) (%)
Exertional physical activity (times/week) 2 (1–2) 2 (1–7) 0.96
BMI (kg/m2) 23.4 (21.3–26.0) 29.9 (26.5–33.5) <0.001
Diabetes duration (yrs) 17.0 (7.5–29.0) 11.0 (7.0–16.0) <0.0001
Over 6 diabetes education sessions (%) 76.3 50 <0.0001
Course in functional insulin therapy (%) 54.7 7.5 <0.0001
Mode of insulin therapy (%) <0.0001
Conventional insulin therapy (fixed insulin doses) 4 31
Basis-bolus insulin therapy (blood glucose adapted insulin doses) 32 57
Functional insulin therapy (insulin doses adapted to blood 64 12
glucose, carbohydrate intake and physical activity)
Continuous subcutaneous insulin infusion (insulin pump) (%) 20.8 1.5 <0.0001
Number of injections/day 4 (4–4) 3 (2–4) <0.001
Skipping injections/week 0.04 (0–0.04) 0 (0–0.04) 0.13
Number of blood glucose measurements/day 4 (3–5) 3 (2–4) <0.0001
Mild hypoglycaemia/day 0.15 (0.03–0.3) 0.02 (0–0.03) <0.001
Severe hypoglycaemia/year 0 (0–1) 0 (0–0) 0.007
HbA1c (%) 7.3 ± 1.0 7.7 ± 1.1 <0.0001
Total diabetic complications (n) 0.4 ± 0.8 0.6 ± 0.9 0.007
Single complications (%):
Sensory polyneuropathy 11 15 0.14
Retinopathy without visual impairment 7 18 <0.0001
Retinopathy with visual impairment 14 19 0.21
Cerebrovascular disease 1 4 0.11
Coronary heart disease 4 10 0.02
Nephropathy 7 6 0.52
Lower limb amputation 1 2 0.58
General quality of life 1.2 ± 1.0 0.7 ± 1.1 <0.0001
Impact of diabetes on quality of life –1.4 ± 1.0 –1.5 ± 1.0 0.22
Internality 40 (34–44) 42 (38–45) <0.001
Treatment facility (generalist/specialist/hospital) (%) 5/26/69 23/15/62 <0.0001
Satisfaction with medical care 3.7 (3.3-3.8) 3.7 (3.5-3.8) 0.56
Table 1
Demographic charac-
teristics of insulin-
treated type 1 and
type 2 diabetic
patients.
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(i.e. 90% power), the maximal sample size calculated to
237 patients in both groups together. 
Data are shown as means ± SD for normally distrib-
uted variables and as median and interquartile ranges for
not normally distributed variables, respectively. Variables
with a skewed distribution were log-transformed. The dif-
ferences in demographic characteristics between type 1
and type 2 diabetic patients were compared by unpaired 
t-test, Mann-Whitney U test or by c2 analysis, as appro-
priate. The main treatment priorities and goals were com-
pared by c2 analysis. 
The influence of the type of diabetes on patients’
treatment goals was assessed by ordinal logistic regression
analysis both unadjusted and after controlling for four
groups: 1) sociodemographic variables, 2) glucose control
and diabetic complications, 3) mode of insulin therapy,
self-monitoring and extent of diabetes education and 4)
psychological variables. We also analysed if allocation of
patients to our outpatient clinic (94% response rate, al-
most no selection bias) vs all other treatment facilities had
an effect on treatment goals. All the analyses were per-
formed using Intercooled STATA (version 8, StataCorp
LP, Texas). Two-tailed p values <0.05 were considered sta-
tistically significant. 
Results
The demographic characteristics of the pa-
tients are shown in table 1. 
Main treatment goals: Differences between
type 1 and type 2 diabetic patients, and
between their own goals and their beliefs
about their physicians’ goals
Overall, type 1 and insulin-treated type 2 dia-
betic patients had significantly different main
treatment goals (p = 0.001) and their main treat-
ment goals were significantly different from what
they felt their physicians’ main goals were (type 1,
p <0.0001; type 2, p = 0.001, respectively, fi-
gure 1A). This difference was noted despite a high
satisfaction with medical care (table 1).
Good long term glucose control was the sin-
gle most important main treatment goal for 56%
of the patients, and its importance as a main treat-
ment goal differed both between type 1 and type 2
diabetic patients (p = 0.025) as well as between
their own and their estimate of their physicians
goals (type 1, p = 0.0001; type 2, p = 0.001, respec-
tively). Breaking the subscale ‘good long term glu-
cose control’ into single elements demonstrated
that patients thought that the value of HbA1c was
much more important for their physicians than for
themselves (type 1, p <0.0001; type 2, p <0.0001,
figure 1B). 
High actual quality of life was the second most
important treatment goal for 24% of the patients
(figure 1A). Patients believed that their quality of
life was more important for them than for their
physicians (type 1, p = 0.003; type 2, p = 0.05, re-
spectively).
Differences in treatment goals between 
type 1 and type 2 diabetic patients
Good long term glucose control and high
actual quality of life were more important for type
1 than for type 2 diabetic patients, while weight re-
duction/maintenance and avoidance of daily has-
sles, such as avoidance of frequent blood glucose
monitoring or of reducing the number of insulin
injections, were slightly more important for pa-
Figure 1
Main treatment goals of type 1 and insulin-treated type 2 diabetic patients and their perception of their physicians’ goals.
A: Overall, main treatment goals differed between type 1 and insulin-treated diabetic patients as well as between their own
goals and their perception of their physicians’ goals (type 1, <0.0001; type 2, p = 0.001, respectively).
Differences in the importance of long term glucose control as a main treatment goal:
+ p <0.025 between type 1 and type 2 diabetic patients 
* p = 0.0001 between type 1 diabetic patients and their physicians
# p = 0.001 between type 2 diabetic patients and their physicians
Differences in the importance of actual quality of life as a main treatment goal: 
* p = 0.003 between type 1 diabetic patients and their physicians
# p = 0.05 between type 2 diabetic patients and their physicians
B: Subanalysis of the main treatment goal subscale “long term glucose control”
Differences in the importance of HbA1c
* p <0.0001 between type 1 diabetic patients and their physicians
# p <0.0001 type 2 diabetic patients and their physicians
A B
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tients with type 2 diabetes (table 2). Adjusting for
sociodemographic variables or for the variables related
to glucose control and diabetic complications did not
eliminate these differences. However, after adjust-
ing for mode of insulin therapy, self-monitoring and
extent of diabetes education (treatment allocation
[generalist, specialist, hospital], number of dia-
betes education sessions, completion of a course in
functional insulin therapy, mode of insulin therapy,
use of an insulin pump, frequency of blood glucose
measurements and insulin injections), the differ-
ences between type 1 and type 2 diabetes regard-
ing these three treatment goals were completely
abolished. The same effect on these treatment
goals was observed when the variables of the mode
of insulin therapy, frequency of self-monitoring
and extent of diabetes education were analyzed
separately (data not shown). Similarly, removing
variables that almost exclusively belong to type 1
diabetic patients such as “use of an insulin pump”
and “completion of a course in functional insulin
therapy” did not alter these results (data not
shown). Adjusting for psychological variables slightly
reduced the differences between the two diabetes
types for the goal “good long term glucose con-
trol”, but had no or almost no effect on the goal 
of attaining or maintaining a “high quality of life”
or the goal “weight reduction/maintenance and
avoidance of daily hassles”. Good medical care and
knowledge was more important for type 1 than for
type 2 diabetic patients, but only after adjustment
for sociodemographic variables. Thus, differences
in mode of insulin therapy, self-monitoring and/or
the extent of diabetes education between patients
with type 1 and type 2 diabetes were best associ-
ated with the differences in treatment goals.
Physical activity, skipping insulin injections,
general treatment allocation (generalist, specialist,
hospital) or allocation of patients to our outpatient
clinic vs all other treatment facilities did not alter
the differences in all four treatment goals between
type 1 and type 2 diabetic patients (data not
shown). Adjusting for BMI slightly reduced the
difference in the treatment goal “weight reduc-
tion/maintenance and avoidance of daily hassles”.
Independent of variables related to the mode of
insulin therapy, self-monitoring and extent of
diabetes education, all four treatment goals were
much more important for patients who felt that a
team approach was very important for their dia-
betes care (data not shown). 
Treatment goals Odds Ratio 95% confidence interval P value
Good long term glucose control
Crude 1.63 1.18–2.25 0.003
Sociodemographic model 1.68 1.13–2.51 0.01
Glucose control & complications model 1.63 1.08–2.47 0.02
Diabetes therapy & education model 1.09 0.69–1.70 0.71
Psychological model 1.38 0.95–1.99 0.09
High actual quality of life
Crude 2.17 1.47–3.22 <0.0001
Sociodemographic model 2.00 1.37–2.94 <0.0001
Glucose control & complications model 1.87 1.25–2.80 0.002
Diabetes therapy & education model 1.22 0.79–1.87 0.37
Psychological model 1.93 1.34–2.77 <0.0001
Weight reduction and daily hassles
Crude 0.75 0.55–1.02 0.07
Sociodemographic model 0.73 0.49–1.07 0.11
Glucose control & complications model 0.70 0.47–1.04 0.07
Diabetes therapy & education model 0.88 0.57–1.34 0.55
Psychological model 0.77 0.54–1.09 0.14
Good medical care and knowledge
Crude 1.01 0.74–1.39 0.95
Sociodemographic model 1.71 1.15–2.55 0.008
Glucose control & complications model 0.97 0.65–1.44 0.88
Diabetes therapy & education model 0.81 0.52–1.26 0.41
Psychological model 0.87 0.61–1.25 0.35
Sociodemographic model: Adjusting for sociodemographic variables (age, sex, level of education, region of origin, employment 
and marital status).
Glucose control & complications model: Adjusting for glucose control and diabetic complications 
(diabetes duration, HbA1c, number of mild and severe hypoglycaemic events, diabetic complications).
Diabetes therapy & education model: Adjusting for mode of insulin therapy, self-monitoring and extent of diabetes education 
(treatment allocation [generalist, specialist, hospital], number of diabetes education sessions, completion of a course in functional insulin
therapy, mode of insulin therapy, use of an insulin pump, frequency of blood glucose measurements and insulin injections).
Psychological model: Adjusting for psychological variables (diabetes-related worries, internality, quality of life).
Table 2
Differences between
Type 1 vs Type 2 pa-
tients regarding their
treatment goals both
unadjusted and ad-
justed in a multiple
ordinal regression
analysis.
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This is the first study to provide extended in-
formation on subjective treatment goals of insulin-
treated type 1 and type 2 diabetic patients. Good
long term glucose control was the single most im-
portant main goal for most patients, but was more
important for subjects with type 1 than type 2 di-
abetes. However, both type 1 and type 2 diabetic
patients believed that long term glucose control –
especially the value of HbA1c – was overempha-
sized, while the actual quality of life was underes-
timated by their physicians compared to them-
selves. Good long term glucose control and high
actual quality of life were more important general
goals, and weight reduction/maintenance and
avoidance of daily hassles were slightly less impor-
tant goals for type 1 compared to type 2 diabetic
patients. These differences were best explained by
the mode of insulin therapy, self-monitoring and
the extent of diabetes education. 
We demonstrated that for insulin-treated pa-
tients, long term glucose control and quality of life
are the most important treatment goals. However,
the patients in this study also thought that their
doctors overemphasized the disease and its long
term complications (good long term glucose con-
trols, value of HbA1c), while neglecting their pres-
ent every-day life (actual quality of life). As the
questionnaire was in part handed out by the care
providers, this could have oriented the results to-
wards even more “physician oriented” treatment
goals (bias of social desirability). One previous
study examining exclusively type 2 diabetic pa-
tients found that normal glucose levels and avoid-
ance of long term complications were the most im-
portant goals for patients and their providers [16].
However, the same study also revealed that the
agreement between patients’ and physicians’ goals
was rather low. Similarly, two other studies re-
ported that physicians overvalued the importance
of metabolic control [16, 17]. Why is there this dif-
ference in therapeutic objectives? Physicians are
trained to treat or prevent diseases. However, in
chronic diseases, the personal everyday life and the
present quality of life have to be weighted against
the impact of the demanded efforts to maintain a
future good quality of life. Often, these personal
impacts, the individual perceptions and under-
standing of the disease are not known or not com-
prehensible to the physicians. In additions, HbA1c
has become a surrogate marker for prevention of
complications in physicians’ daily practice, as it is
easier to talk about this than to discuss complica-
tions. For many patients, however, HbA1c is not a
measure of long-term glucose control and per-
sonal risk for complications, but rather a measure
of poor behaviour. Indeed, our patients believed
that prevention of complications was at least as im-
portant for themselves as it was for their physi-
cians, while the value of HbA1c was only half as
important. What could be done to improve these
differences? Knowing the patients’ personal set-
tings and their goals and engaging them actively 
in setting the common goals, helps to specifically
address their individual perceptions, improve their
understanding, but also to adjust the providers’
goals. Patient-centred therapeutic groups such as
functional insulin therapy group courses are an
ideal environment to address these questions.
Regarding the HbA1c, physicians could try to
enhance their patients’ understanding of this value
as a measure of long-term glucose control, and not
a measure of poor performance. 
Knowing the patients’ goals and promoting a
greater agreement on treatment goals and strategies
on both sides, can improve the patient-provider
collaboration and lead to improved outcomes [8,
16, 18–21]. Actively engaging patients in setting
treatment goals encourages patient understanding
and motivation to follow treatment plans, in-
creases self-management and provides a reference
against which success can be measured [8, 16, 18,
20–28]. Even if some discrepancy in treatment
goals persists, the role of the provider in a patient-
centred environment is also to provide patients
with the necessary knowledge so that they can
define and reach their own goals. 
Patients with type 1 diabetes chose “good long
term glucose control” more often as their single
most important main treatment goal than patients
with type 2 diabetes. For patients with type 2 dia-
betes, the management of other cardiovascular risk
factors or the reduction in weight might be at least
as important as glycaemia control. As we studied
both type 1 and type 2 diabetic patients and fo-
cused on insulin therapy, we only used one ques-
tionnaire for both types of diabetes and unfortu-
nately did not list other cardiovascular risk factors
as treatment goals in this questionnaire. Another
limitation of this anonymous study is that the data
are self-reported. This could be relevant for some
of the variables like the number of diabetic com-
plications or the value of HbA1c. 
For patients with type 1 diabetes, “good long
term glucose control” and “high actual quality of
life” were more important treatment goals and
“weight reduction/maintenance and avoiding daily
hassles” were slightly less important goals com-
pared to the goals of type 2 diabetic patients. These
differences were best associated with the mode of
insulin therapy, self-monitoring and extent of dia-
betes education. Based on these data, we hypothe-
size that subjects who undergo more extensive
diabetes education and subjects who are more
engaged with their diabetes learn to better define,
understand and weigh their goals, and may choose
those goals that agree with those of their providers.
Potentially, patients with more extensive diabetes
education might be more biased by what they have
been told by their providers. There could also be
another bias, as those patients who are primarily
Discussion
interested in attaining a good long term glucose
control are also interested in having more diabetes
education sessions and agree to inject insulin and
measure blood glucose more frequently. 
In conclusion, we could demonstrate that for
insulin-treated type 1 and type 2 diabetic patients
long term glucose control is the single most im-
portant main treatment goal. Nevertheless, pa-
tients believed that physicians overestimate the
importance of long term glucose control, espe-
cially the value of HbA1c, and underestimate the
importance of the actual quality of life. Differences
in treatment goals between type 1 and type 2 dia-
betic patients were best associated with the extent
of diabetes education and differences in self-man-
agement. This leads us to believe that diabetes ed-
ucation and self-management have a major influ-
ence on assisting the patient to set their own treat-
ment goals, increase the mutual patient-provider
agreement on goals and subsequently improve
outcome. Future studies will show us the value of
incorporating patients’ treatment goals in diabetes
care in improving metabolic control, quality of life
and satisfaction with medical care in patients with
diabetes. 
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